New Delhi: Drug Controller General Of India (DCGI) gave a restricted emergency use approval to the Zydus Cadila’s ‘Virafin’ for treating the patients showing moderate COVID-19 symptoms. Virafin is a pegylated interferon alpha-2b(PegIFN), which when s
SHENZHEN, China, April 20, 2021 /PRNewswire/ As a national, internationalized and comprehensive exhibition and negotiation occasion for the exchange of international technological innovation and talents, the 19th Conference on International Exchange of Professionals (CIEP) is to be held in Shenzhen Convention & Exhibition Center on April 24 and 25, based on the theme of innovation, development, cooperation, and win-win .
The CIEP has been successfully held for 18 sessions so far. This year, it is set to host organizations, institutions, companies and talents from around the world with a new look.
Focusing on offline venues, this 19th CIEP will integrate online and offline platforms for a more connected and boundaries exchanging experience for all parties. Exhibitions, forums and summits, recruiting events, project matching opportunities, virtual meetings and other themed activities build this year s CIEP a comprehensive platform for communicating, cooperating and trading on th
At a time when India is grappling with second wave of coronavirus, the union government on Friday announced manifold increase in production capacity of Covaxin in the coming months. The production capacity is expected to reach nearly 100 million doses per month by September 2021 from the existing 10 million doses. Government of India is providing financial support as grant to vaccine manufacturing facilities for enhanced production capacities. The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021 i.e increasing the production from 10 million vaccine doses in April, 2021 to 60-70 million vaccine doses/month in July–August. It is expected to reach nearly 100 million doses per month by September 2021, said Ministry of Science & Technology in a statement.
By Reuters Staff
1 Min Read
FILE PHOTO: Indian Health Minister Harsh Vardhan holds a dose of Bharat Biotech s COVID-19 vaccine called COVAXIN, during a vaccination campaign at All India Institute of Medical Sciences (AIIMS) hospital in New Delhi, India, January 16, 2021. REUTERS/Adnan Abidi//File Photo
NEW DELHI (Reuters) - India said on Friday monthly production capacity of its homegrown COVID-19 shot will be raised to nearly 100 million doses by September, as it tries to overcome a shortage amid a record surge in cases.
“The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021,” the Ministry of Science & Technology said in a statement, pegging current capacity at 10 million doses.
Besides Bharat Biotech, three other state-run companies will also be provided financial support to increase vaccine production.
Haffkine Biopharmaceutical Corp., a firm run by the Maharashtra government, will be provided Rs 65 crore to get its facility ready for producing vaccine doses. The company had asked about 12 months to start manufacturing. However, the central government has asked them to expedite and complete the task within six months. The facility, once functional, will be able to produce 2 crore doses every month.
The government will also support Hyderabadâs Indian Immunologicals Ltd. and Bulandshahrâs Bharat Immunologicals and Biologicals Ltd. to prepare their facilities for producing vaccines. These facilities will be able to produce up to 1-1.5 crore doses every month by August-September 2021.